Connor, Clark & Lunn Investment Management (CC&L)
PRLD icon

Connor, Clark & Lunn Investment Management (CC&L)’s Prelude Therapeutics PRLD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373K Buy
109,085
+62,995
+137% +$165K ﹤0.01% 1369
2025
Q4 		$134K Buy
+46,090
New +$77.8K ﹤0.01% 1469
2024
Q4 		– Sell
-17,293
Closed -$35.8K – 1596
2024
Q3 		$35.8K Buy
17,293
+4,948
+40% +$22.9K ﹤0.01% 1391
2024
Q2 		$47K Sell
12,345
-7,721
-38% -$31.4K ﹤0.01% 1330
2024
Q1 		$95.1K Buy
+20,066
New +$78.1K ﹤0.01% 1468

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PRLD Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Prelude Therapeutics (PRLD) stake by 137% in Q1 2026, buying an estimated $165K and bringing the position to 109,085 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1369.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PRLD in Q1 2024 and has held it in 5 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 109,085 shares of Prelude Therapeutics worth $373K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 62,995 Prelude Therapeutics shares in Q1 2026, an estimated $165K.
  • Prelude Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1369 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Prelude Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.